Wellington Management Group LLP Buys 59,700 Shares of Enfusion, Inc. (NYSE:ENFN)

Wellington Management Group LLP grew its holdings in shares of Enfusion, Inc. (NYSE:ENFN - Free Report) by 6.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,035,996 shares of the company's stock after purchasing an additional 59,700 shares during the quarter. Wellington Management Group LLP owned about 0.81% of Enfusion worth $10,671,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Arrowstreet Capital Limited Partnership acquired a new position in Enfusion during the 4th quarter worth $2,358,000. JPMorgan Chase & Co. lifted its stake in shares of Enfusion by 45.8% in the fourth quarter. JPMorgan Chase & Co. now owns 303,332 shares of the company's stock valued at $3,124,000 after buying an additional 95,310 shares during the period. Fox Run Management L.L.C. bought a new stake in shares of Enfusion in the 4th quarter worth approximately $265,000. KLP Kapitalforvaltning AS acquired a new stake in Enfusion during the fourth quarter worth $75,000. Finally, Quantbot Technologies LP bought a new position in Enfusion during the fourth quarter worth about $144,000. Institutional investors and hedge funds own 81.05% of the company's stock.

Enfusion Trading Up 0.8 %

Shares of ENFN traded up $0.09 during midday trading on Tuesday, reaching $10.90. The stock had a trading volume of 161,004 shares, compared to its average volume of 616,761. The firm has a market cap of $1.41 billion, a PE ratio of 272.44, a P/E/G ratio of 1.85 and a beta of 0.92. The firm has a 50 day simple moving average of $11.10 and a 200-day simple moving average of $10.38. Enfusion, Inc. has a one year low of $7.83 and a one year high of $11.80.

Enfusion (NYSE:ENFN - Get Free Report) last issued its quarterly earnings data on Monday, March 3rd. The company reported $0.01 earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.02). The company had revenue of $52.94 million during the quarter, compared to the consensus estimate of $53.98 million. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. As a group, research analysts forecast that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Insider Buying and Selling

In other Enfusion news, CEO Oleg Movchan sold 2,790 shares of the business's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $11.48, for a total transaction of $32,029.20. Following the sale, the chief executive officer now directly owns 643,299 shares of the company's stock, valued at $7,385,072.52. The trade was a 0.43 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Bradley Herring sold 4,645 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total value of $52,860.10. Following the transaction, the chief financial officer now owns 324,689 shares of the company's stock, valued at $3,694,960.82. This trade represents a 1.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 66,223 shares of company stock worth $754,778. Company insiders own 36.44% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ENFN shares. William Blair reaffirmed a "market perform" rating on shares of Enfusion in a report on Monday, January 13th. Stifel Nicolaus raised their price objective on shares of Enfusion from $11.00 to $13.00 and gave the company a "buy" rating in a research note on Wednesday, December 18th. Finally, Piper Sandler boosted their target price on Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research report on Monday, December 23rd.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.